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alkenes – synthesis of citalopram†
Joanne F. M. Hewitt, Lewis Williams, Pooja Aggarwal, Craig D. Smith
and David J. France*
A palladium-catalyzed difunctionalization of unactivated alkenes with tethered nucleophiles is reported.
The versatile reaction occurs with simple allylic halides and can be carried out under air. The
methodology provides rapid access to a wide array of desirable heterocyclic targets, as illustrated by a
concise synthesis of the widely prescribed antidepressant citalopram.Introduction
Palladium-catalyzed heterocyclization onto alkenes holds
particular importance for synthetic chemists because of the
complexity formed, the generally tolerant reaction conditions,
and the prevalence of the heterocyclic products in bioactive
targets.1 The s-alkyl Pd(II) intermediate formed by hetero-
cyclization can participate in a range of subsequent trans-
formations including b-hydride elimination (Wacker-type
reaction), alkoxycarbonylation, Heck reaction, or proto-
demetallation.1j In addition to these pathways, when the het-
erocyclization is preceded by oxidative addition, a reductive
elimination can complete the catalytic cycle.2 Recently, strate-
gies have emerged that involve oxidation of the s-alkyl Pd(II)
intermediate formed by heterocyclization (particularly with
hypervalent iodine reagents)3 as a means of subsequently
forming new C–halogen,4 C–O,5 C–N,6 and C–C6f,7 bonds.
When a Pd(II)-induced heterocyclization onto an unactivated
alkene is followed by C–C bond formation, the new C–C bond is
typically to an sp2-hybridized carbon (e.g. 2/ 3, Scheme 1).8,9
Extending this methodology to form sp3–sp3 C–C bonds wouldfollowed by C–C bond formation.
ity of Glasgow, Joseph Black Building,
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3constitute a signicant advance, in part because increasing the
sp3-C content of preclinical drug candidates has been identied
as a potential strategy to improve clinical success rates.10 Pd-
catalyzed allylation is a powerful method for C–C bond forma-
tion that has seen widespread use in the construction of an
impressive array of complex targets;11 however, this method has
never been coupled to the Pd(II)-induced heterocyclization onto
unactivated alkenes. In this communication, we report the
catalyzed reaction of unactivated alkenes with tethered oxygen
or nitrogen nucleophiles and allylic halides to generate a new
fully substituted carbon center and a new sp3–sp3 C–C bond.
Furthermore, we demonstrate the utility of this method with a
synthesis of the widely prescribed selective serotonin reuptake
inhibitor (SSRI) citalopram.Results and discussion
Optimization
The combination of alkenyl phenol 5 with the commercially
available catalyst Pd(hfacac)2 was selected for initial screening
of the planned heteroallylation based on precedent in other
oxypalladation reactions (Table 1).7b Gratifyingly, benzofuran 6
was observed when the reaction with allyl bromide was con-
ducted in THF, though conversion was relatively low aer 72 h
(entry 1). Solvent screening revealed that ca. 80% conversion
could be achieved in PhMe aer 16 h (entry 2). Attempting to
use alternative Pd catalysts (entries 3–6), or allylic electrophiles
(entries 7, 8) resulted in substantially lower conversions. By
replacing allyl bromide with allyl chloride,9 full conversion was
observed in 6 h (entry 9). Decreasing catalyst loading to 5 mol%
resulted in increased reaction time, but full conversion was still
observed aer 16 h (entry 10).12 It should be noted that the
optimized conditions can be conducted under ambient atmo-
sphere using solvent directly as procured.13 From a mechanistic
point of view, it is noteworthy that only trace amounts of
dihydrobenzofuran 6 formed when using a Pd(0) catalyst (entry
11, vide infra).This journal is ª The Royal Society of Chemistry 2013
Table 1 Optimization of the Pd-catalyzed heteroallylation
Entrya Pd cat. (loading) X Solvent Time 5 : 6b
1 Pd(hfacac)2 (10 mol%) Br THF 72 h 2 : 1
2 Pd(hfacac)2 (10 mol%) Br PhMe 16 h 1 : 4.3
3 Pd(OAc)2 (10 mol%) Br PhMe 22 h 19 : 1
4 Pd(acac)2 (10 mol%) Br PhMe 22 h 12 : 1
5 Pd(TFA)2 (10 mol%) Br PhMe 22 h N. R.
c
6 PdCl2 (10 mol%) Br PhMe 28 h 1 : 2
7 Pd(hfacac)2 (10 mol%) OAc PhMe 18 h N. R.
c
8 Pd(hfacac)2 (10 mol%) I PhMe 18 h 5 : 1
9 Pd(hfacac)2 (10 mol%) Cl PhMe 6 h <1 : 20
10 Pd(hfacac)2 (5 mol%) Cl PhMe 16 h <1 : 20
11 Pd2(dba)3 (10 mol%) Br PhMe 18 h N. R.
c
a Reaction conditions: 5 (1 equiv.), allyl-X (5 equiv.), Pd cat., NaHCO3
(2 equiv.), 50 C, solvent (0.25 M). b Determined by 1H NMR
integration of crude reaction mixtures. c No reaction. 5 : 6 20 : <1.
Table 2 Pd-catalyzed heteroallylation using phenols
Entrya Substrate Product Time Yieldb
1 16 h 70%
2 24 h 75%c
3 23 h 74%
4 24 h 67%
5 16 h 71%
6 20 h n.d.d
a Reaction conditions: substrate (1 equiv.), allyl chloride (5 equiv.),
Pd(hfacac)2 (5 mol%), NaHCO3 (2 equiv.), PhMe (0.25 M), 50 C.
b Isolated yield. c Reaction carried out on 0.9 g scale. d Yield not
determined.
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View Article OnlineSubstrate scope
With these optimized conditions in place, we sought to examine
the scope of this heteroallylation reaction to make substituted
dihydrobenzofurans (Table 2). The unsubstituted case provided
the allylation product in 70% isolated yield (entry 1). Substitu-
tion ortho to the reacting oxygen and inclusion of electron-
withdrawing substituents were tolerated without decrease in
yield (entries 2–4).14 Of particular importance is the successful
heteroallylation in the presence of an aryl bromide (entry 5),
which can serve as a handle for the subsequent introduction of
a vast array of functionality. When attempting to utilize a
monosubstituted alkene, only trace oxyallylation product
was detected, with the major product arising from b-hydride
elimination from the putative s-alkyl Pd(II) intermediate (entry
6, vide infra).15
Next, we chose to further probe the scope of the hetero-
allylation reaction by examining the formation of heterocycles
other than dihydrobenzofuran (Table 3). Use of the previously
optimized reaction conditions with a benzylic alcohol led to a
relatively low overall yield (entry 1).16 Fortunately, recourse to
allyl bromide resulted in a cleaner reaction prole, with the
desired isobenzofuran being obtained in 77% isolated yield
(entry 2). Steric hindrance about the unactivated alkene did not
prove to be an impediment to the hetroallylation reaction
(entry 4). The dihydroisobenzopyran ring system could also be
assembled using this methodology (entry 5).17 Use of a substrate
containing an unprotected hydroxyl group that was not involved
in the heterocyclization resulted in low conversion with allyl
bromide; however, using allyl chloride for this substrate resul-
ted in a synthetically viable yield (entries 7, 8). Secondary and
tertiary alcohols, as well as benzoic acids also performed well in
the reaction (entries 9–14). It should be highlighted that
substitution on the unactivated alkene can include sp3-C
(including a sterically encumbering t-Bu group), or an aromaticThis journal is ª The Royal Society of Chemistry 2013ring.18 Once again, when attempting the oxyallylation with a
monosubstituted alkene, cyclization followed by b-hydride
elimination occurred in relatively low conversion, with none of
the allylated lactone being observed (entry 15).15
We then attempted to extend the method to an amino-
allylation by cyclization of tosyl amides onto unactivated
alkenes (Scheme 2). These eﬀorts were initially plagued by low
conversion on gem-disubstituted alkene precursors even at
prolonged reaction times with 10 mol% catalyst loading.
However, we were successfully able to access the isoquinolone
(8b) and pyrrolopyrazinone (8c) ring systems from mono-
substituted alkene precursors without signicant b-hydride
elimination.15 Modication of the base to KH2PO4 was required
for these aminocyclizations in order to suppress N-allylation.Mechanistic hypothesis
Although the precise mechanism for this heteroallylation
reaction is yet to be fully elucidated, we have carried out
preliminary studies designed to test the possible intermediacy
of a p-allyl species. An experiment using dideuteroallyl bromide
labelled at the allylic position resulted in exclusive formation of
a product with two vinyl deuterons (Scheme 3).15Chem. Sci., 2013, 4, 3538–3543 | 3539
Table 3 Pd-catalyzed alkene heteroallylation of unactivated alkenes
a Reaction conditions: substrate (1 equiv.), allyl-X (5 equiv.), Pd(hfacac)2
(5 mol%), NaHCO3 (2 equiv.), PhMe (0.25 M), 50 C.
b Isolated yield
except where noted. c Yield at full conversion based on 1H NMR
integration, compound contaminated with additional impurities. d An
additional 5 mol% catalyst was added. e Carried out in d8-toluene;
yield based on 1H NMR integration vs. internal standard. f d.r. ¼
1.4 : 1 see ESI for all assignments. g d.r. ¼ 1.3 : 1. h d.r. ¼ 1.5 : 1. i Low
conversion to a mixture of products, see ESI.
Scheme 2 Aminoallylation substrates and conditions.
Scheme 3 Deuterium labelling study.
Scheme 4 Postulated catalytic cycle.
3540 | Chem. Sci., 2013, 4, 3538–3543
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View Article OnlineFurthermore, while not denitive, the lack of reactivity using
Pd2dba3, coupled with the fact that precipitation of Pd(0) was not
observed during the course of the reactions and the tolerance of
the process for aryl halides (which might have undergone
oxidative addition to an in situ-generated Pd(0) species) suggests
that Pd(0) intermediates are not involved.13 These factors lead us
to propose the following catalytic cycle (Scheme 4): Pd(II)-induced
heterocyclization (9/ 10)mightbe followedby carbopalladation
of the allyl halide to generate Pd(II)-alkyl complex 11.1,19 Subse-
quent b-halide elimination (which has been shown to occurmore
rapidly than b-hydride elimination in several systems9,20) would
then aﬀord heteroallylation product 12, while releasing the Pd(II)
catalyst.21 This mechanistic interpretation is consistent with
results obtained in related cyclizations of allenes.9e,g,hSynthesis of citalopram
In order to demonstrate the utility of the heteroallylation
methodology for the preparation of bioactive heterocycles, andThis journal is ª The Royal Society of Chemistry 2013
Scheme 5 Synthesis of citalopram using oxyallylation.
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View Article Onlinefurther probe substrate scope, a synthesis of the SSRI cit-
alopram was performed (Scheme 5).22,23 The reaction of p-uo-
rophenyl Grignard reagent 14 with commercially available
cyanophthalide 13 is known from the patent literature.23c,f
Subsequent Wittig reaction provided the requisite alkenyl
alcohol 15. The pivotal Pd-catalyzed oxyallylation proceeded
in good yield to furnish isobenzofuran 16. Conversion of
terminal alkene 16 to citalopram was readily achieved by one-
pot dihydroxylation–oxidative cleavage,24 followed by reductive
amination.Conclusions
In summary, we have developed a versatile catalytic hetero-
allylation reaction of unactivated alkenes to form heterocycles
that are prevalent in a plethora of targets including natural
products and bioactive compounds. The process forms a fully
substituted carbon center and a new sp3–sp3 C–C bond in a
single step, and occurs using a commercially available catalyst
under operationally convenient conditions (e.g. under air). The
orthogonality of the newly described heteroallylation to stan-
dard Pd(0)-catalyzed processes (as illustrated by the tolerance
of the reaction for aryl halides, and lack of reactivity with a
Pd(0) catalyst) clearly shows the potential for this method to
be used in accessing complex targets. Phenols, alcohols,
carboxylic acids and tosyl amides are all competent nucleo-
philes for this transformation, which we have also shown can
be employed in a synthesis of the bioactive heterocycle cit-
alopram. Ongoing investigations in our group seek to further
expand the scope of the reaction, including ligand-based
control of enantioselectivity, and explore the mechanism
underpinning the process.Acknowledgements
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